AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK

Solna, Sweden and Lugano, Switzerland, April 13, 2023 AnaCardio, a Swedish clinical-stage  biopharmaceutical company focussed on developing novel contractile agents with a unique mode of-action based on the ghrelin signaling pathway, today announced that the first patient has been  successfully dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced  ejection […]